Farallon Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
|
|||||
|
2024
Q1 | $299K | Hold |
|
|||||
|
2023
Q4 | $383K | Hold |
|
|||||
|
2023
Q3 | $354K | Hold |
|
|||||
|
2023
Q2 | $380K | Sell |
|
|||||
|
2023
Q1 | $1.35M | Sell |
|
|||||
|
2022
Q4 | $30.9M | Sell |
|
|||||
|
2022
Q3 | $85.8M | Sell |
|
|||||
|
2022
Q2 | $115M | Sell |
|
|||||
|
2022
Q1 | $167M | Sell |
|
|||||
|
2021
Q4 | $202M | Buy |
|
|||||
|
2021
Q3 | $154M | Sell |
|
|||||
|
2021
Q2 | $161M | Buy |
|
|||||
|
2021
Q1 | $98.8M | Buy |
|
|||||
|
2020
Q4 | $45.5M | Sell |
|
|||||
|
2020
Q3 | $175M | Buy |
|
|||||
|
2020
Q2 | $156M | Sell |
|
|||||
|
2020
Q1 | $163M | Buy |
|
|||||
|
2019
Q4 | $167M | Sell |
|
|||||
|
2019
Q3 | $121M | Buy |
|
|||||
|
2019
Q2 | $79.8M | Buy |
|
|||||
|
2019
Q1 | $46.7M | Sell |
|
|||||
|
2018
Q4 | $40.1M | Buy |
|
|||||
|
2018
Q3 | $24.2M | Sell |
|
|||||
|
2018
Q2 | $40.9M | Buy |
|
|||||
|
2018
Q1 | $44.1M | Buy |
|
|||||
|
2017
Q3 | – | Sell |
|
|||||
|
2017
Q2 | $16M | Buy |
|